You just read:

VistaGen Therapeutics Announces Positive Preclinical Data of AV-101 Combined with Probenecid Suggesting Substantially Increased Brain Concentration Effects

News provided by

VistaGen Therapeutics

Feb 11, 2020, 08:30 ET